Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database

Megan E B Clowse, Angela E Scheuerle, Christina Chambers, Anita Afzali, Alexa B Kimball, John J Cush, Maureen Cooney, Laura Shaughnessy, Mark Vanderkelen, Frauke Förger, Megan E B Clowse, Angela E Scheuerle, Christina Chambers, Anita Afzali, Alexa B Kimball, John J Cush, Maureen Cooney, Laura Shaughnessy, Mark Vanderkelen, Frauke Förger

Abstract

Objective: Anti-tumor necrosis factor (anti-TNF) medications are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently, anti-TNF agents are often discontinued early in gestation. Certolizumab pegol (CZP), a PEGylated, Fc-free anti-TNF agent approved for the treatment of rheumatic diseases and/or Crohn's disease, has minimal to no active placental transfer. This analysis was undertaken to evaluate pregnancy outcomes in women receiving CZP, especially those exposed during early pregnancy.

Methods: Prospective and retrospective data on maternal CZP exposure were extracted from the UCB Pharma safety database through March 6, 2017. Analysis was limited to prospective reports to avoid potential bias associated with retrospective submissions. The numbers of live births, miscarriages, elective abortions, stillbirths, and major congenital malformations were ascertained.

Results: Of 1,137 prospectively reported pregnancies with maternal exposure to CZP, 528 (including 10 twin pregnancies) had 538 known outcomes: 459 live births (85.3%), 47 miscarriages (8.7%), 27 elective abortions (5.0%), and 5 stillbirths (0.9%). There were 8 major congenital malformations (1.7%) among the 459 infants. First trimester exposure occurred in 367 (81.2%) of 452 pregnancies resulting in 459 live births. Exposure during all 3 trimesters occurred in 201 (44.5%) of 452 pregnancies.

Conclusion: This analysis represents the largest cohort of pregnant women exposed to an anti-TNF agent for management of chronic inflammatory diseases. Analysis of pregnancy outcomes does not indicate a teratogenic effect of CZP, compared to the general population, nor an increased risk of fetal death. The data are reassuring for women of childbearing age considering treatment with CZP.

© 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College ofRheumatology.

Figures

Figure 1
Figure 1
Overview of pregnancies exposed to certolizumab pegol (CZP). Eleven patients were included in more than 1 treatment indication category (rheumatic diseases, Crohn's disease, or other) due to multiple reported indications. RA = rheumatoid arthritis; AS = ankylosing spondylitis; axSpA = axial spondyloarthritis; PsA = psoriatic arthritis; JIA = juvenile idiopathic arthritis.
Figure 2
Figure 2
Known outcomes for prospectively reported pregnancies with maternal exposure to certolizumab pegol. Ten twin pregnancies are included in the total number of pregnancy outcomes (4 in mothers with rheumatic diseases, 5 in mothers with Crohn's disease [CD], and 1 in a mother with unknown indication). Miscarriage was defined as embryonic or fetal death before 20 weeks of gestation. Induced abortion includes both elective and medically indicated abortions.
Figure 3
Figure 3
Trimesters of maternal certolizumab pegol (CZP) exposure for prospectively reported pregnancies resulting in a live birth. A, Timing of CZP exposure for all pregnancies. A total of 452 pregnancies resulted in a live birth, including those in which the mother was exposed preconception (n = 5; CZP exposure stopped >14 days and ≤70 days prior to the first trimester) and pregnancies for which the timing of exposure could not be determined (n = 8), as well as 1 patient exposed in the first and third trimesters. Black, dark gray, and light gray shading represent CZP exposure during the first, second, and third trimesters, respectively; shading gradients reflect exposure during multiple trimesters. B, Exposure by indication for CZP use. There were 8 live births for which the timing of exposure could not be determined (n = 2 for patients with rheumatic disease and n = 6 for patients with Crohn's disease).

References

    1. Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, et al. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken) 2015;67:313–25.
    1. Chakravarty E, Clowse ME, Pushparajah DS, Mertens S, Gordon C. Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. BMJ Open 2014;4:e004081.
    1. Van den Brandt S, Zbinden A, Baeten D, Villiger PM, Ostensen M, Forger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther 2017;19:64.
    1. Pedersen N, Bortoli A, Duricova D, D Inca R, Panelli MR, Gisbert JP, et al. The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO‐EpiCom study of 209 pregnant women. Aliment Pharmacol Ther 2013;38:501–12.
    1. Boyd HA, Basit S, Harpsoe MC, Wohlfahrt J, Jess T. Inflammatory bowel disease and risk of adverse pregnancy outcomes. PLoS One 2015;10:e0129567.
    1. McConnell RA, Mahadevan U. Pregnancy and the patient with inflammatory bowel disease: fertility, treatment, delivery, and complications. Gastroenterol Clin North Am 2016;45:285–301.
    1. Jakobsson GL, Stephansson O, Askling J, Jacobsson LT. Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis 2016;75:1838–42.
    1. Ma KK, Nelson JL, Guthrie KA, Dugowson CE, Gammill HS. Adverse pregnancy outcomes and risk of subsequent rheumatoid arthritis. Arthritis Rheumatol 2014;66:508–12.
    1. Norgaard M, Larsson H, Pedersen L, Granath F, Askling J, Kieler H, et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med 2010;268:329–37.
    1. De Man YA, Dolhain RJ, van de Geijn FE, Willemsen SP, Hazes JM. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum 2008;59:1241–8.
    1. Mouyis MA, Thornton CC, Williams D, Giles IP. Pregnancy outcomes in patients with psoriatic arthritis. J Rheumatol 2017;44:128–9.
    1. Polachek A, Li S, Polachek IS, Chandran V, Gladman D. Psoriatic arthritis disease activity during pregnancy and the first‐year postpartum. Semin Arthritis Rheum 2017;46:740–5.
    1. Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology 2017;152:451–62.e2.
    1. Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research. Womens Health Issues 2013;23:e39–45.
    1. Flint J, Panchal S, Hurrell A, van de Venne M, Gayed M, Schreiber K, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding‐Part I: standard and biologic disease modifying anti‐rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2016;55:1693–7.
    1. Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009;5:382–90.
    1. Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer‐Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810.
    1. Clowse ME, Wolf DC, Forger F, Cush JJ, Golembesky A, Shaughnessy L, et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol 2015;42:2270–8.
    1. Medicines and Healthcare products Regulatory Agency . Best practice in reporting of individual case safety reports (ICSRs). London: Medicines and Healthcare products Regulatory Agency; 2011.
    1. National Institutes of Health Office of Communications . About pregnancy. January 2017. URL: .
    1. Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990–2008. Natl Vital Stat Rep 2012;60:1–21.
    1. European surveillance of congenital anomalies (EUROCAT) web site. URL: .
    1. Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, et al. Pregnancy and foetal outcomes following anti‐tumor necrosis factor α therapy: a prospective multicentre study. Joint Bone Spine 2017;84:169–73.
    1. Mahadevan U, Martin CF, Sandler RS, Kane SV, Dubinsky M, Lewis JD, et al. 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012;142:S–149.
    1. Weber‐Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers‐Maarschalkerweerd B, et al. Pregnancy outcome after TNF‐α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727–39.
    1. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013;170:1–7.
    1. DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007–2010. Prev Chronic Dis 2014;11:E104.
    1. Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, de Longueville M, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis 2015;74:96–103.
    1. Loftus EV Jr, Colombel JF, Schreiber S, Randall CW, Regueiro M, Ali T, et al. Safety of long‐term treatment with certolizumab pegol in patients with Crohn's disease, based on a pooled analysis of data from clinical trials. Clin Gastroenterol Hepatol 2016;14:1753–62.
    1. Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24‐week results of a Phase 3 double‐blind randomised placebo‐controlled study (RAPID‐PsA). Ann Rheum Dis 2014;73:48–55.
    1. Van der Heijde D, Dougados M, Landewe R, Sieper J, Maksymowych WP, Rudwaleit M, et al. Sustained efficacy, safety and patient‐reported outcomes of certolizumab pegol in axial spondyloarthritis: 4‐year outcomes from RAPID‐axSpA. Rheumatology (Oxford) 2017;56:1498–509.
    1. Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, et al. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology 2016;150:734–57.e1.
    1. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti‐tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286–92; quiz e24.
    1. Martin JA, Hamilton BE, Osterman MJ, Driscoll AK, Mathews TJ. Births: final data for 2015. Natl Vital Stat Rep 2017;66:1.
    1. Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti‐tumor necrosis factor‐α use in females with immune mediated diseases; a systematic review and meta‐analysis. J Autoimmun 2017;76:38–52.
    1. Ostensen M. Contraception and pregnancy counselling in rheumatoid arthritis. Curr Opin Rheumatol 2014;26:302–7.
    1. Cimzia summary of product characteristics. URL: .
    1. Electronic Medicines Compendium . Cimzia. URL: .
    1. Cimzia prescribing information. Smyrna (GA): UCB; 2016.
    1. Calligaro A, Hoxha A, Ruffatti A, Punzi L. Are biological drugs safe in pregnancy? Reumatismo 2015;66:304–17.
    1. Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti‐tumor necrosis factor‐α agents in rheumatic diseases: a systematic review and meta‐analysis. J Autoimmun 2017;79:4–16.
    1. Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto‐maternal interface. Rev Reprod 1999;4:81–9.
    1. Porter C, Armstrong‐Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn‐mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 2016;116:7–12.
    1. European Medicines Agency/Committee for Medicinal Products for Human Use . Guidelines on risk assessment of medicinal products on human reproduction and lactation: from data to labelling. URL: .
    1. MotherToBaby: medications & more during pregnancy & breastfeeding web site. URL: .

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner